tbuckley/cabot-search huggingface dataset:
New Appliance.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE TREATMENT OF DIABETES.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Enzyme Changes Induced in Normal and Malignant Tissues with Chemical Agents. V. Effect of Acetylpodophyllotoxin-&lt;italic&gt;ω&lt;/italic&gt;-Pyridinium Chloride on Uricase, Adenosine Deaminase, Nucleoside Phosphorylase, and Glutamic Dehydrogenase Activities
Authors: V. S. Waravdekar, Anita D. Paradis, J. Leiter
Journal: JNCI Journal of the National Cancer Institute (1955)

Enzyme Changes Induced in Normal and Malignant Tissues with Chemical Agents. V. Effect of Acetylpodophyllotoxin-ω-Pyridinium Chloride on Uricase, Adenosine Deaminase, Nucleoside Phosphorylase, and Glutamic Dehydrogenase Activities Get access V. S. Waravdekar, V. S. Waravdekar Laboratory of Chemical Pharmacology, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Anita D. Paradis, Anita D. Paradis Laboratory of Chemical Pharmacology, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Leiter J. Leiter Laboratory of Chemical Pharmacology, National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 1, August 1955, Pages 99–105, https://doi.org/10.1093/jnci/16.1.99 Published: 01 August 1955 Article history Received: 03 December 1954 Published: 01 August 1955
In Reply
Authors: Merrill Egorin, Ramesh K. Ramanathan, Joseph Gibbons, William Petros, S. Percy Ivy, Scot C. Remick
Journal: Journal of Clinical Oncology (2008)

P ϭ .0152).This finding is consistent with a previous study indicating that the clearance of paclitaxel was impaired in a patient with endstage renal failure, 15 similar to the findings with imatinib, 2 but not in an anephric patient on dialysis. 16 The findings reported by Gibbons et al 2 support a growing body of evidence that renal failure can dramatically impact the pharmacokinetics of agents for which elimination is critically dependent on metabolism in the liver.Future studies should further evaluate the hypothesis that increased systemic concentrations of uremic toxins can directly inhibit the hepatic uptake of several anticancer agents, and that consideration of this type of interaction can guide the design and interpretation of dose-finding studies in patients with renal dysfunction.
Diagnosis-related groups for physician reimbursement?
Authors: M. J. Segal
Journal: JAMA (1985)

Diagnosis-related groups (DRGs) are being considered by policymakers as a basis of physician reimbursement for care provided to Medicare inpatients. Under such a system, all physicians' care associated with a hospital admission, classified into one of over 400 DRGs, would be paid for by Medicare in one lump sum. The attractiveness of aggregating the unit of payment, from the individual service to a "package" of services, here the hospital case, lies in the anticipation of new incentives for greater physician cost consciousness. The report by Lowenstein and colleagues<sup>1</sup>in this issue ofThe JOURNALis one product of an intensive effort, launched by the Department of Health and Human Services and its Health Care Financing Administration, to fulfill a congressional mandate to explore the "advisability and feasibility" of extending Medicare DRG payment, already in place for hospitals, to physicians. The conclusions from this research are to be presented in
&lt;TITLE&gt;Syphilis&lt;/TITLE&gt;
Journal: JAMA (2000)

public service of JAMA and the AMA.The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis.For specific information concerning your personal medical condition, JAMA and the AMA suggest that you consult your physician.This page may be reproduced noncommercially by physicians and other health care professionals to share with patients.Any other reproduction is subject to AMA approval.
Abstract 5269: Discovery and validation of plasma acylcarnitines for the early diagnosis of hepatocellular carcinoma
Authors: Eric Yi-Liang Shen, Abellona U, Simon Taylor-Robinson, Mark Thursz, Elaine Holmes, Jeremy Nicholson
Journal: Cancer Research (2019)

Abstract Introduction: Hepatocellular carcinoma (HCC) is one of the commonest and the leading cause of cancer death globally. The main cause of this high mortality rate is that patients with HCC are usually diagnosed at late stages since they have only subtle clinical presentations at early stages. This late diagnosis is a result of the requirement of high-end imaging modalities, the use of invasive procedures, and the lack of reliable tumour biomarkers. Metabolomics is the study of metabolites in an organism in response to the changes in health status. The purpose of this study was to identify and validate plasma acylcarnitines as potential diagnostic biomarkers of HCC by using techniques in the field of metabolomics. Methods: 228 EDTA-plasma samples of healthy controls, cirrhotic patients, or treatment-naïve patients with HCC, collected from Imperial College Healthcare Tissue Bank, were used as a discovery and training set. Patient factors, including basic patient characteristics, aetiologies of HCC, and Child-Pugh scores, and data relating to tumours, such as the multiplicity, the sizes in diameter, the status of macro-vascular invasion, were collected. A targeted assay was adapted to measure concentrations of carnitine and acylcarnitines with different chain length using the TQ-S tandem quadrupole mass spectrometer. Non-parametric univariate analyses were applied to evaluate the statistical difference between HCC and cirrhosis. Logistic regression was preferred to develop diagnostic models. A Gambian cohort of 165 plasma samples was then used as an external validation. Results: Among sixteen measured carnitine and acylcarnitines, three acylcarnitines, namely acetylcarnitine, succinylcarnitine, and hexanoylcarnitine, statistically increased in HCC patients comparing to cirrhotic patients. A linear model incorporating these three acylcarnitines and alpha-fetoprotein was then developed. The area under the ROC curve of this multivariable regression model was 0.782 (95% C.I., 0.695-0.870) in the training set. When applied to the validation cohort, the sensitivity and specificity of this model at identifying HCC patients from cirrhosis were 82.2% and 67.8%, respectively. Conclusion: This report provides a comprehensive profile of the changes of carnitine and acylcarnitines among HCC, cirrhotic patients and healthy controls, and determines the value of acylcarnitines as diagnostic biomarkers for HCC. Citation Format: Eric Yi-Liang Shen, Abellona U, Simon Taylor-Robinson, Mark Thursz, Elaine Holmes, Jeremy Nicholson. Discovery and validation of plasma acylcarnitines for the early diagnosis of hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5269.
James D. Waltner, MD: doctor for small planet
Authors: E. R. Gonzalez
Journal: JAMA (1980)

In the emergency room last night, 13-year-old Tommy was screaming and vomiting. He had gulped down half a 10-oz bottle of Nyquil, and the ephedrine was wreaking havoc with him. This morning he has only a very bad hangover—and a visitor. The visitor, who is presently stopping by the nurse's station en route to Tommy's hospital room, is an ordained minister in the Universal Life Church, a conscientious objector, a talented musician, and an expert in animal husbandry who finds a flock of dependent but misanthropic geese preferable to watchdogs for guarding his wood-and-solar-heated home in the mountains of northern New Mexico. James D. Waltner, MD, is also pediatrician, adopted uncle, surrogate parent, and health educator to hundreds of families in Rio Arriba County, one of the most economically depressed areas in the nation. Most of his patients are direct descendents of the Spanish<i>conquistadores</i>. A few are Native American
Physiology.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Editorial Position and US Health System Reform
Authors: M. G. Jacoby
Journal: JAMA (1994)

<h3>To the Editor.</h3> —The Editorial<sup>1</sup>by Dr Lundberg suggests that in his ideal world referral to a specialist or subspecialist be made only by the primary care physician. This is completely impracticable. Under most health maintenance organization plans, the primary care physician is supposed to act as a gatekeeper, but in fact this does not work. It merely means more effort wasted in purely bureaucratic administration, making out referral slips and calling up a clerk at the insurance company to get permission. Even if the specialist referral is unnecessary, no sensible physician would refuse a patient's request. If he or she did so, the patient would lose confidence and go to another primary care physician who would accede to the patient's wishes. The suggestion that primary care physicians not be given hospital admitting privileges is unsatisfactory. Often, a hospitalized patient does not require the care of the specialist, apart
Identification of a new hepatitis virus (HGV) and its implication in post transfusion hepatitis 2. Genelabs Technologies, Inc1., Redwood City, CA, National Institutes of Health2, Bethesda, MD, Centers for Disease Control and Prevention3, Atlanta, GA, NSW Blood Transfusion Sevice4, Sydney, Australia, and Naval Medical Research Institute5, Bethesda, MD
Journal: Hepatology (1995)

Viral hepatitis refers to inflammatory liver diseases caused by viral infections. Worldwide 600 million individuals are chronically or acutely infected with liver-tropic viruses. Six viruses that cause viral hepatitis have been identified, and ordered alphabetically according to their discovery from hepatitis A virus (HAV) to hepatitis G virus (HGV). Importantly, each of these viruses belongs to distinct virus families, except that hepatitis C virus (HCV) and HGV belong to the family Flaviviridae. HAV and hepatitis E virus (HEV) cause self-limiting acute infections, while hepatitis B virus (HBV) and HCV can cause acute infections and lifelong, persistent chronic infections. Persistent HBV and HCV infections can lead to severe liver diseases including liver cirrhosis and cancer. Here, we focus on clinical features of these hepatitis viruses regarding epidemiology, transmission, diagnosis, clinical course of infection, and treatment.
DENITROGENIZING THE ATMOSPHERE.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PRICE OF MEDICAL BOOKS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ARETAEUS, THE CAPPADOCIAN
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outbreak of Poliomyelitis--Dominican Republic and Haiti, 2000-2001
Journal: JAMA (2001)

During July 12-November 18, 2000, 19 persons with acute flaccid paralysis (AFP) were identified in the Dominican Republic, including six laboratory-confirmed cases with poliovirus type 1 isolates. Of the 19 case-patients, 16 (84%) were aged < or = 6 years (range: 9 months-21 years). All case-patients were either unvaccinated (n=14) or inadequately vaccinated (n=5). In Haiti, a single laboratory-confirmed poliovirus type 1 case was reported in an inadequately vaccinated child aged 2 years; paralysis onset was August 30. Despite intensive case-finding activities, no additional cases have been identified.
对过敏性皮肤炎使用全身用糖皮质激素:国际湿疹理事会共识声明
Authors: A.M. Drucker, K. Eyerich, M.S. de Bruin-Weller, J.P. Thyssen, P.I. Spuls, A.D. Irvine, G. Girolomoni, S. Dhar, C. Flohr, D.F. Murrell, A.S. Paller, E. Guttman-Yassky
Journal: British Journal of Dermatology (2018)

过敏性皮肤炎,通常称为湿疹,是一种瘙痒性皮肤病,影响着美国7%的儿童和10%的成人。病情严重者通常难以治疗。皮质类固醇(例如强的松)是一类药品,医生指导方针中通常不推荐其口服形式(例如药片)。这与类固醇(例如霜和药膏)相反,后者是过敏性皮肤炎的推荐一线治疗药物。医生会给许多患有严重的过敏性皮肤炎的患者开具全身用糖皮质激素,尽管在大部分病例中都不推荐使用。然而许多此类处方都是不恰当的,因为这些药物具有副作用,也因为这些药物停用之后皮肤病会进一步恶化。我们的研究目标是就何时且如何将全身用糖皮质激素用于治疗过敏性皮肤炎方面在专家中达成一致。来自20个国家/地区的60名国际湿疹理事会成员参与了我们的调查并就12项声明达成一致。专家们一致认为应普遍避免使用全身用糖皮质激素,但可在某些情况下少量用于严重的过敏性皮肤炎,包括缺少其他治疗方法时、用作全身治疗或光线疗法的过渡、需要迅速缓解痛苦的病情恶化情况、参加重大生活事件(例如婚礼)时或在大多数严重的病例中。参与调查的专家表示,即使使用,也应限制在短期内。我们希望我们的论文能够对皮肤科医生、过敏症专科医师、儿科医师、主治医生和治疗过敏性皮肤炎患者的任何其他保健服务提供者有所帮助。希望我们的研究能够减少对全身用糖皮质激素的不当使用并改善过敏性皮肤炎患者的状况。
Laboratory Investigation, New York
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2463: Impact of Donor to Recipient Weight Ratio on Survival after Heart Transplantation: Analysis of the United Network for Organ Sharing Database
Authors: Nishant D Patel, Eric S Weiss, Lois U Nwakanma, Stuart D Russell, William A Baumgartner, Ashish S Shah, John V Conte
Journal: Circulation (2007)

Introduction : Accepted donor criteria for heart transplantation limit allografts to donors within 20–30% of the recipient’s weight. We analyzed the impact of donor to recipient (DR) weight ratio on survival after heart transplantation. Methods : Adult heart transplant recipients reported to the United Network for Organ Sharing from 1999–2007 were divided into 3 groups based on DR weight ratio: &lt;0.8, 0.8–1.2, and &gt;1.2. Kaplan-Meier methodology was used to estimate survival. Propensity-adjusted Cox regression modeling was used to analyze predictors of mortality. Results : 15284 heart transplant recipients were analyzed: 2078 had weight ratio of &lt;0.8, 9684 had 0.8–1.2, and 3522 had &gt;1.2. Survival was not statistically different between groups (Figure ). Among patients with weight ratio &lt;0.8, survival was lower for recipients with high pulmonary vascular resistance (PVR) (&gt;4 Woods units) (Figure ). Among recipients with high PVR, 5-year survival was similar for those with weight ratio 0.8–1.2 and &gt;1.2 (p =0.44 ). Propensity-adjusted multivariable analysis demonstrated that weight ratio &lt;0.8 did not predict mortality (HR 1.09; 95% CI 0.94–1.27; p =0.21). Five-year survival after propensity matching was not statistically different between those with weight ratio &lt;0.8 versus ≥0.8 ( p =0.37). Conclusions : Weight ratio did not predict mortality after heart transplantation. Undersized allografts in recipients with normal/low PVR did not adversely effect survival. Oversized allografts in recipients with high PVR did not provide survival advantage over normal-sized allografts. Extending donor criteria to include undersized hearts in select recipients should be considered.
All that sweetens is not sugar.
Journal: BMJ (1969)

Leading ArJicles MWCL JOURNAL hernia' has the advantage of allowing any other intraabdominal lesion to be treated.Good results have been reported from the transthoracic approach.8In the absence of associated duodenal ulcer there is little evidence to suggest that patients with reflux oesophagitis have greater than normal secretion of acid, and though there are advocates of vagotomy with gastric drainage in addition to repair of the hiatus there is no convincing proof that this is necessary.Indeed, D. A. W. Edwards and his colleagues,' in a dispassionate review carried out by a group of physicians of these surgical procedures, found little to choose between patients who had undergone transthoracic and those who had transabdominal repair, while surgical attempts to reduce acid secretion did not seem to improve the results.During an 11-year period they found that 50 of their 63 patients who had been operated on, all with severe reflux resistant to medi- cal treatment, were well pleased with the operative result.Thus the chances that the symptoms of reflux will be relieved by surgery are high even when only the most severe cases are submitted to operation.